Financial Health Snapshot
What does Zoetis latest financial snapshot show?
Mixed. The strongest factor is still-profitable scale in animal health, while the main concern is weaker cash flow growth and pressure in U.S. companion-animal demand.
The latest verified period is Q1 2026, and this verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. For broader context on the company’s purpose, see Mission Statement, Vision, & Core Values (2026) of Zoetis Inc. (ZTS).
Free Cash Flow deserves deeper analysis first because negative growth, not revenue alone, is the clearest warning sign for near-term flexibility.
Revenue and earnings quality
Are Zoetis Inc. revenue and earnings still durable?
Zoetis Inc. looks Mixed. FY2025 and Q1 2026 both show strong top-line and per-share growth, but Q1 2026 also showed pressure in U.S. and companion animal sales, so the clearest confirmation is recurring animal-health demand and the clearest divergence is weaker U.S. momentum.
Investors care about both how fast revenue grows and how clean that growth is. Zoetis Inc. has a recurring animal-health model, but they still compare revenue durability with operating income, net income, and EPS across compatible periods to see whether growth turns into lasting profit instead of temporary volume or mix gains.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $947B in FY2025, Revenue Growth of 227% | Not provided in the prompt | Organic growth is unclear at the full-year level | Large growth can be repeatable if driven by recurring vet demand, but the source split matters |
| Operating Income | Not provided in the prompt | Not provided in the prompt | Unable to verify against revenue | No operating-leverage test can be confirmed from the supplied data |
| Net Income | $267B in FY2025, Net Income Growth of 752% | Not provided in the prompt | Strong, but full operating and non-operating drivers are not fully shown | Bottom-line growth confirms profit expansion, but not all of it can be traced from the prompt |
| Diluted EPS | Reported Diluted EPS of $602 in FY2025, EPS Growth of 1005% | Not provided in the prompt | Per-share growth was helped by Weighted Average Shares Growth of -367% and Weighted Average Shares Diluted Growth of -369% | Share reduction boosted per-share results, so EPS ran ahead of underlying net income |
How durable is Zoetis Inc. revenue?
The strongest durability signal is Zoetis Inc.’s recurring direct-to-veterinarian model across chronic care biologics, diagnostics, and companion and livestock products. The biggest visibility limit is concentration in U.S. companion animal demand, which weakened in Q1 2026.
- Demand Quality: Recurring animal-health demand is supported by vet channels and repeat treatment, but Q1 2026 showed pressure in U.S. companion animal sales.
- Pricing and Volume: The prompt gives overall growth and regional results, but not a clean price-volume split.
- Diversification: Zoetis Inc. sells across dogs, cats, horses, cattle, poultry, swine, fish, and sheep, with over 15 blockbuster products.
That mix supports cash conversion if margins hold, which is why investors also watch profitability and share count.
Cash Conversion
Does Zoetis convert profit into cash reliably?
No, not cleanly. Profit remained substantial at the 2026-03-31 level, but Gross Profit Growth of -140%, Operating Income Growth of -048%, EBITDA Growth of -063%, and Net Income Growth of -033% show pressure, while Operating Cash Flow Growth of -5510% and Free Cash Flow Growth of -6025% do not confirm steady cash conversion.
Zoetis Inc. (ZTS) still posted strong reported earnings, with $226B revenue, $162B gross profit, $82200M operating income, and $60100M net income at 2026-03-31, but cash quality looks weaker than earnings quality. Gross profit reflects product economics, operating income reflects overhead and R&D discipline, and net income reflects interest and tax effects. For company background, see Zoetis Inc. (ZTS): History, Ownership, Mission, How It Works & Makes Money.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Not provided; latest gross profit was $162B at 2026-03-31. | Not provided. | Gross Profit Growth of -140% signals pricing, mix, or cost pressure. | Product economics look under pressure, so gross profit is not expanding cleanly. |
| Operating Margin | Not provided; latest operating income was $82200M at 2026-03-31. | Not provided. | Operating Income Growth of -048% suggests leverage was weaker despite revenue support. | Scale is not clearly improving operating efficiency. |
| Net Margin | Not provided; latest net income was $60100M at 2026-03-31. | Not provided. | Interest Expense of $6200M and Income Tax Expense of $15700M affected final profit. | Final profitability is positive, but it is not enough to prove strong cash conversion. |
| Operating Cash Flow | Growth of -5510%. | Previous value not provided. | Receivables Growth of -528% and Inventory Growth of 494% point to working-capital pressure. | Accounting earnings are not translating into stronger operating cash flow. |
| Free Cash Flow | Growth of -6025%. | Previous value not provided. | Growth Capital Expenditure of 3168% increased reinvestment demand. | After capital spending, cash available for debt paydown, buybacks, or flexibility looks weaker. |
What most affects Zoetis cash conversion?
Working-capital pressure and higher reinvestment appear to be the biggest drivers, especially the -528% receivables change, 494% inventory change, and 3168% growth capital expenditure.
- Main Driver: Working capital and capex look like a structural cash drag, not just a one-quarter issue.
- Evidence Gap: The supplied data does not give operating cash flow, capex, or free cash flow dollar amounts.
- Metric to Monitor: Follow operating cash flow growth and free cash flow growth next quarter.
Balance Sheet Strength
Can Zoetis fund operations, debt, dividends, and buybacks from its balance sheet?
Zoetis looks Mixed. Cash and current assets support day-to-day spending, but $924B of total debt and heavy goodwill and intangibles limit flexibility. The main protection is $194B in cash and short-term investments; the main concern is sustaining cash generation for payouts and debt service. Exploring Zoetis Inc. (ZTS) Investor Profile: Who's Buying and Why?
Cash alone is not enough here. Zoetis needs enough working capital, asset quality, debt service capacity, liquidity, and refinancing access to keep investing while still paying shareholders. The balance sheet looks solid on near-term liquid assets, but leverage and intangible-heavy assets mean the real test is ongoing operating cash flow.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash and Cash Equivalents were $194B; Short Term Investments were $000; Cash And Short Term Investments were $194B; Net Receivables were $151B; Inventory was $255B; Other Current Assets were $47700M; Total Current Assets were $647B. | Strong | Near-term obligations look manageable, so operations and investment should not depend on emergency liquidity. |
| Total and Net Debt | Minus Cash And Cash Equivalents was $194B and Add Total Debt was $924B at 2026-03-31; Total Debt moved from $949B at 2025-12-31 to $924B at 2026-03-31. | Mixed | Debt is still meaningful, even with the recent decline, so leverage can constrain flexibility for buybacks, dividends, and new investment. |
| Debt Service and Refinancing | No maturities, rates, or refinancing schedule were supplied; the data set does show continuing cash use for $606M of Q1 2026 share buybacks and a $053 per share dividend. | Mixed | Zoetis appears able to fund obligations only if operating cash remains steady, but refinancing pressure cannot be judged from the supplied data. |
| Asset Quality | Property Plant Equipment Net was $400B; Goodwill was $278B; Intangible Assets were $95900M; Goodwill And Intangible Assets were $374B; Total Non Current Assets were $868B; Total Assets were $1515B. | Mixed | Asset quality is acceptable, but the goodwill and intangible load means book value may not be as flexible as the asset total suggests. |
| Liabilities and Equity | Total liabilities and shareholders' equity were not fully supplied in the prompt; the verified asset base was $1515B, with debt of $924B in the enterprise value data. | Mixed | The capital base appears sizable, but the missing liability detail limits how precisely investors can judge loss-absorbing capacity. |
Which balance-sheet risk matters most for Zoetis?
The main risk is leverage and payout pressure. Zoetis has solid liquidity, but the combination of $924B of debt, $606M of share buybacks, and a $053 per share dividend makes continued cash generation the key variable.
- Current Exposure: Cash And Short Term Investments were $194B against $924B of total debt at 2026-03-31.
- Protection: Total Current Assets were $647B, which supports near-term operating needs.
- Warning Signal: Watch whether debt and shareholder returns keep rising faster than cash generation.
Capital Efficiency
Are Zoetis Inc. returns and reinvestment financially sustainable?
Zoetis Inc. looks Mixed, not clearly strong. Internal cash appears helpful, but the reinvestment load is heavy, so sustainability depends on cash flow recovery and continued operating strength rather than current cash alone.
Return quality has to be read with leverage, asset intensity, capital expenditure, working capital, and any outside funding needs. ROIC reflects returns on operating capital, ROE reflects returns to shareholders after leverage, and ROA shows profit from total assets. Zoetis Inc. has to keep funding growth without letting reinvestment outrun cash generation.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data. | Operating margins and capital efficiency cannot be scored from a provided ROIC figure. | Investors cannot confirm whether invested capital is creating operating value from the available data. |
| ROE and ROA | Unavailable in the supplied data. | ROE would reflect leverage, while ROA would reflect how much profit Zoetis Inc. earns from its asset base. | Without these values, shareholder return quality and asset efficiency remain unverified. |
| Maintenance and Growth Investment | R&D expense of $711M in 2025; Research And Development Expenses of $18000M for 2026-03-31; R&D reinvestment of approximately 740% of 2025 revenue; Lenivia and Portela approvals; H5N2 vaccine conditional U.S. and Canadian licenses; $5B total addressable market opportunity in chronic kidney disease, oncology, and cardiology. | Heavy R&D points to major growth investment, not just maintenance spending. | Capital appears aimed at pipeline expansion, which can support long-run returns if approvals convert into durable sales. |
| Internal Funding Capacity | Total Capital Returned was over $41B in 2025; Annual Share Buybacks were $324B; Q1 2026 Share Buybacks were $606M; Q1 2026 dividend was $053 per share after a 600% increase; Q3 2026 Dividend was $053 per share; Number Of Shares of 42210M at 2026-03-31 versus 43820M at 2025-12-31. | Buybacks and dividends show strong shareholder distributions, but sustainability depends on free cash flow covering both returns and reinvestment. | Share repurchases can support per-share results through a lower share count, but heavy payouts reduce flexibility if cash flow weakens. |
Are Zoetis Inc. returns on capital sustainable?
They look sustainable only if product launches, pipeline progress, and cash flow stay strong. The strongest durability source is the veterinary and pipeline mix; the main weakness would be rising R&D and payout demands without matching cash generation.
- Operating Source: Margin support comes from approvals such as Lenivia and Portela, plus H5N2 vaccine licenses and the $5B opportunity set.
- Funding Requirement: The largest verified capital need is the high R&D burden, including $711M in 2025 and $18000M at 2026-03-31.
- Durability Test: Returns weaken if free cash flow stops covering R&D, buybacks, and dividends while the share count stops falling.
Financial Resilience
How resilient is Given Company, and which warning signs matter most?
Resilience is Mixed. The main buffer is Zoetis’s global scale across more than 100 countries, two geographic segments, 27 manufacturing sites, and eight core species. The most important verified warning sign is weaker U.S. companion animal demand, with Q1 2026 U.S. revenue falling 800% to $11B and companion animal sales declining 1100%.
Zoetis still has room to protect liquidity and fund essential investment because international revenue grew 1700% reported and 1000% organic to $11B, and management kept full year 2026 guidance intact. The strain is that falling U.S. companion animal sales, pressure in chronic pain franchises, and weaker cash generation can reduce flexibility if they persist.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Lower U.S. companion animal sales can hurt operating leverage, earnings, cash flow, and debt capacity if pricing and volume both weaken. | International revenue growth, especially Simparica Trio, gives Zoetis some offset and keeps demand diversified. | Further U.S. revenue declines, margin compression, or weaker cash flow would confirm deterioration. |
| Working-Capital or Investment Pressure | Lower operating cash flow can limit R&D, product support, and expansion without leaning more on internal funding. | Zoetis’s broad species mix and global manufacturing footprint support ongoing operations. | Continued declines in operating cash flow, free cash flow, or rising investment needs are the key signals. |
| Interest or Refinancing Pressure | Weaker free cash flow would narrow financing flexibility and make debt service more sensitive if conditions tighten. | No verified near-term funding stress is supplied, and the company still has global scale and operating reach. | Rising debt pressure, weaker interest coverage, or tighter liquidity would show increasing strain. |
What financial warning signs should investors monitor at Given Company?
The top signals are U.S. companion-animal revenue, free cash flow growth, and guidance changes. Confirmed deterioration is already visible in weaker U.S. demand and cash flow; the securities class action is a separate overhang, not a verified accounting loss.
Weak U.S. Companion Animal Demand
Q1 2026 U.S. revenue fell 800% to $11B and companion animal sales declined 1100%, showing real pressure from competition in dermatology and parasiticides. Watch whether U.S. companion-animal revenue stabilizes or keeps falling.
Cash Flow Slippage
Operating Cash Flow Growth of -5510% and Free Cash Flow Growth of -6025% point to cash pressure that could limit flexibility. The offset is ongoing international growth, but free cash flow is the next metric that matters most.
Litigation Overhang
A securities class action filed May 06, 2026 and disclosure litigation tied to Librela, Apoquel, and Cytopoint may weigh on sentiment and legal costs. It is not a confirmed financial loss in the supplied data, so case progress is the metric to monitor.
Financial Health Scorecard
What does Zoetis financial health mean for investors?
Zoetis earns a Mixed score. The strongest factor is its profitable global animal health platform; the weakest is cash conversion and US companion-animal pressure. The most important condition for the investment case is free cash flow, because it supports R&D, dividends, buybacks, and flexibility. For background, Zoetis Inc. (ZTS): History, Ownership, Mission, How It Works & Makes Money.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | FY2025 revenue was $947B, Q1 2026 revenue was $23B, but US revenue fell 800% and Q1 2026 net income growth was 000%. |
| Profitability and Cash | Mixed | 2026-03-31 gross profit was $162B and operating income was $82200M, but operating cash flow growth was -5510% and free cash flow growth was -6025%. |
| Balance Sheet and Liquidity | Mixed | Cash and cash equivalents were $194B and total current assets were $647B, while total debt was $924B, so liquidity exists but leverage stays relevant. |
| Capital Efficiency | Strong | Buybacks, dividends, and R&D reinvestment remain active, which supports capital use, but weaker cash flow growth means funding discipline matters more. |
| Financial Resilience | Mixed | International growth and diversification help offset US companion-animal pressure, guidance cuts, and litigation overhang, but the cushion is narrower if cash flow stays weak. |
- What Supports the Thesis: Profitable global animal health demand still funds R&D, dividends, and buybacks.
- What Challenges the Thesis: Slower cash conversion and US companion-animal weakness could limit flexibility.
- What to Monitor: Q1 2026 US companion-animal revenue trend, Free Cash Flow Growth, and Organic Operational Revenue Growth guidance.
Forecasts should focus on whether growth, cash conversion, and litigation costs stay stable enough to support scenario-based valuation work.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How strong is Zoetis cash generation now?
Zoetis remains profitable, but cash generation weakened in the latest FMP period Operating Cash Flow Growth was -5510% and Free Cash Flow Growth was -6025% for 2026-03-31 Investors should separate this cash pressure from net income, which was $601M
Does Zoetis have liquidity for buybacks?
Zoetis had Cash And Cash Equivalents of $194B and Cash And Short Term Investments of $194B at 2026-03-31 It also repurchased $606M of shares in Q1 2026 Continued buybacks depend on cash flow recovery and debt discipline
How much debt pressure does Zoetis carry?
Enterprise Values data show Add Total Debt of $924B at 2026-03-31 and Cash And Cash Equivalents of $194B No debt maturities, rates, or coverage ratios were supplied, so investors should avoid unsupported refinancing conclusions
Are Zoetis shareholder returns still funded internally?
Zoetis returned over $41B to shareholders in 2025 through dividends and repurchases, including Annual Share Buybacks of $324B Q1 2026 Share Buybacks were $606M Internal funding looks possible, but weaker free cash flow growth deserves close monitoring
What makes Zoetis financially resilient despite pressure?
Zoetis has global diversification, operations in over 100 countries, 27 manufacturing sites, and revenue across eight core species International revenue grew 1700% reported in Q1 2026, helping offset US companion-animal weakness and guidance pressure